A Biogen adquiriu a IDEC Pharmaceuticals e passou a chamar-se Biogen IDEC. É mais uma biotecnológica, a segunda maior do NDX com 1,9505%, a seguir à Amgen que está no 8º posto.
« Biogen IDEC Inc. Formerly known as IDEC Pharmaceuticals Corp.. The Group's principal activity is the research, development, manufacture and commercialization of targeted therapies for the treatment of cancer and autoimmune and inflammatory diseases. The Group's two commercial products, Rituxan (r) (rituximab) and Zevalin (r) (ibritumomab tiuxetan) are for use in the treatment of certain B-cell non-Hodgkin's lymphomas (B-cell NHLs). Rituxan is a genetically engineered, chimeric murine/human monoclonal antibody designed to harness the patient's own immune mechanisms to destroy normal and malignant B cells. Zevalin, the Group's radioimmunotherapy product approved for treatment of certain B-cell NHL, delivers targeted immunotherapy by means of injectable radiation to target sites expressing the CD20 antigen, such as lymphatic B-cell tumors. In addition, the Group is developing products for the treatment of cancer and various autoimmune and inflammatory diseases, such as rheumatoid arthritis, allergic asthma and allergic rhinitis.»
A BIIB tem vindo a subir bastante nos últimos meses, tendo ali um enorme gap no gráfico de longo prazo. Num relance pelas contas a valorização da empresa parece absurda, sem nexo ... mas já se sabe como são estas biotech.
O Clubeinvest.com informa que nenhuma da informação
aqui facultada deverá ser entendida como conselho ou recomendação
de qualquer tipo de transacção ou investimento.
